- Conditions
- Exercise-Induced Anemia, Physical Performance
- Interventions
- Epoetin Alfa
- Drug
- Lead sponsor
- United States Army Research Institute of Environmental Medicine
- Federal
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Natick, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 42
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anemia, Chronic Kidney Disease, Kidney Disease
- Interventions
- Darbepoetin Alfa, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more
- Conditions
- Infant, Newborn
- Interventions
- Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 1 Hour to 49 Hours
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Ogden, Utah • Salt Lake City, Utah
- Conditions
- Anaemia
- Interventions
- Daprodustat, Darbepoetin alfa, Iron therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 36
- States / cities
- Anaheim, California • Cerritos, California • Escondido, California + 31 more
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Darbepoetin alfa
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 68
- States / cities
- Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Darbepoetin alfa
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more
- Conditions
- Lymphoma
- Interventions
- darbepoetin alfa, filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 60 Years to 120 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- HIV Infections, Cytopenias
- Interventions
- Filgrastim, Epoetin alfa, Zidovudine
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections, Cytopenias
- Interventions
- Epoetin alfa
- Drug
- Lead sponsor
- Ortho Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Raritan, New Jersey
- Conditions
- Anemia
- Interventions
- Mircera, Darbepoetin alfa
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 11
- States / cities
- Granada Hills, California • Lauderdale Lakes, Florida • Augusta, Georgia + 8 more
- Conditions
- Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
- Interventions
- Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Up to 3 Days
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Traumatic Brain Injury
- Interventions
- Erythropoietin
- Drug
- Lead sponsor
- Uniformed Services University of the Health Sciences
- Federal
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Athletes
- Interventions
- EPOGEN® (epoetin alfa), Normal Saline
- Drug · Other
- Lead sponsor
- Sports Medicine Research and Testing Laboratory
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Anemia
- Interventions
- Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more
- Conditions
- Myelodysplastic Syndrome, Anemia
- Interventions
- Elritercept, Epoetin Alfa
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 31
- States / cities
- Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more
- Conditions
- Spinal Ischemia, Stroke, Neuroprotection
- Interventions
- Darbepoetin alfa, Standard care
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
- Interventions
- Darbepoetin alfa, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 254
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more
- Conditions
- Anemia
- Interventions
- Epoetin alfa 3 times weekly /once weekly, Epoetin alfa once weekly, Epoetin alfa once every two weeks
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 61
- States / cities
- Glendale, Arizona • Tempe, Arizona • Chula Vista, California + 58 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 337
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 260 more
- Conditions
- Anemia Associated With Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa, Epoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Escondido, California • Denver, Colorado • Fort Lauderdale, Florida + 7 more
- Conditions
- Anemia, Chronic Kidney Disease (CKD)
- Interventions
- HX575 epoetin alfa, US-licensed epoetin alfa
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 52
- States / cities
- Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more
- Conditions
- Anaemia
- Interventions
- Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
- Conditions
- Anemia
- Interventions
- placebo, epoetin alpha, Niferex
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Cranbury, New Jersey • East Brunswick, New Jersey
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Interventions
- peginesatide
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more